Hints and tips:
Related Special Reports
...Obese and overweight patients clamouring for Novo Nordisk’s weight-loss and diabetes drugs have helped the Danish drugmaker grow into Europe’s most valuable company....
...The ruling came after Escobar Inc, the company set up by his brother, filed an application in 2021 with the European Union Intellectual Property Office (EUIPO) for registration of the word sign Pablo Escobar...
...The company has genetically validated two other drug targets....
...insurers to cover the drug....
...Drugs companies issued 1,643 warnings of impending shortages in 2023, compared to 648 in 2020, the research found....
...The company’s immunotherapy drug Imfinzi helped patients with so-called limited stage small cell lung cancer survive for longer....
...The company said the decision was partly driven by huge demand for weight-loss drugs....
...Finding an effective treatment for Alzheimer’s has proved fiendishly difficult for drug companies, and previous regulatory decisions in the field have stirred controversy....
...A top EU court has ruled that the name of the dead Colombian drug kingpin Pablo Escobar cannot be registered as a trademark in the EU....
...Soaring sales of the products have pushed the companies’ valuations to record highs....
...Scientists have invented a potential drug candidate that successfully combats antibiotic-resistant “superbugs” in non-human tests, according to research....
...The debate over the role of obesity drugs has not yet been settled. In February’s mid-stage trials, Eli Lilly’s weight loss drug tirzepatide showed promise against MASH....
...Bobby Gaspar, co-founder and chief executive of Orchard, said Lenmeldy was “a paradigm-shifting medicine”, adding that the company was “committed to enabling broad, expedient and sustainable access to this...
...Patients with terminal breast cancer in England will miss out on a new drug already approved in Scotland, after spending watchdog NICE said Enhertu, developed by Japanese pharma company Daiichi Sankyo and...
...Instead, drugs companies will be on the hook for an uncapped 20 per cent share of catastrophic costs....
...“NHS England expected drug companies AstraZeneca and Daiichi Sankyo to offer this treatment at a price that would enable Nice to recommend its use,” NHS England said....
...Chief executive Lars Fruergaard Jørgensen told the Financial Times this month that it was assessing deals for biotech companies with mid-stage drugs....
...Sales of cancer drugs helped AstraZeneca to beat City expectations in 2023, as the FTSE 100 company forecast continued double-digit sales growth in 2024....
...But according to Holst, who has worked as a consultant for the company, it has struggled to develop small-molecule GLP-1 drugs, which are much easier and cheaper for manufacturers to produce at scale....
...The company plans to “move forward as quickly as possible” with further trials in MASH for the drug....
...company....
...For that reason, the 2023 FT Person of the Year went to Lars Fruergaard Jørgensen, chief executive of Novo Nordisk, the pharmaceutical company that brought these successful weight-loss drugs to market....
...With new production facilities typically taking several years to come online, companies are leaning heavily on contract manufacturers....
...drug-related offences in the past two years....
...Ain’s shares jumped this week, following a filing suggesting Oasis could make “important proposals” to the company....
International Edition